Setting Standards Empowering Research Building Shareholder Value Investor Presentation January 2025

Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates”, “targets” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding financial outlook and business performance, including related to revenues, net loss and adjusted EBITDA, growth, margin and operating expenses; statements regarding future financial performance and expectations, operational and strategic plans, deployment of capital, cash runway and sufficiency of cash resources, potential market and growth opportunities, and future potential M&A activity; the potential to realize the expected benefits of prior and potential future acquisitions, our 2025 and 2026 financial targets, including with respect to revenue, non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, adjusted EBITDA, cash, and free cash flow; the competitive ability and position of the company, the success, cost and timing of the company’s product development, sales and marketing, and research and development activities, the company’s ability to obtain and maintain regulatory approval for its products, the sufficiency of the company’s cash, cash equivalents and short-term investments to fund operations, and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks and uncertainties related to, among other things, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring plans, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; our ability to achieve future financial targets; changes in our business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to our research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of our most recent annual report on Form 10-K filed with the SEC on March 1, 2024. We undertake no obligation to revise or update any forward-looking statements for any reason. Non-GAAP financial information Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis. The non-GAAP financial measures included in this presentation are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this presentation. Trademarks Standard BioTools, the Standard BioTools logo, Biomark, CyTOF, CyTOF XT, EP1, Helios, Hyperion, Hyperion+ and SomaScan are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation)or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Standard BioTools 3 OUR APPROACH Operate as OWNERS, act like INVESTORS “Increase ROI, Diversify Risk & Generate Returns” Focus on EFFICENCY to grow PROFITS “Without Margin, there is no Mission” Offer SOLUTIONS that enable “We are a business not a technology or 'omics application”

Strategy: Attract, Consolidate, Operate Amass Talent, Build a Diversified Solutions Leader, Deliver Operational Excellence Consolidate: High-Value Products & Solutions targeting High-Growth, High-Margin, End- Markets Talent recruited from all the leading Life Science Companies + ~200 yrs of experience Two acquisitions, $174M FY '24 revenue and $311M Q3’24 net-cash to target new M&A1,2 Leverage: Standard BioTools Systems (SBS) to Drive Business Execution, Efficiency, and Profitability $100M in operationalized cost reduction across the two acquisitions3 , targeting adjusted EBITDA positive in 2026 4 Assemble: Team of World Class Leaders focused on Delivering Shareholder Return 1Net cash as of Q3 '24; Cash net of convertible debt that was paid off on November 29, 2024 2The unaudited, preliminary 2024 financial results presented above, including revenue, gross margin for FY 2024 and cash and cash equivalents as of December 31, 2024, are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company’s financial results for Q4 or FY 2024 and remains subject to the completion of financial closing procedures and internal reviews. 3This refers to the Fluidgm and Somalogic acquisitions

Michael Egholm, PhD Chief Executive Officer Experience: • Danaher • Pall • Roche Alex Kim Chief Financial Officer Experience: • Danaher • Pall • Milliken Sean Mackay Chief Business Officer Experience: • IsoPlexis • PhenomeX • Lazard Agnieszka Gallagher SVP, Chief Legal Officer Experience: • Sandoz • Alnylam • GSK Betsy Jensen Chief H.R. Officer Experience: • Danaher • Gibraltar • ITW Stephen Williams, MD PhD Chief Medical Officer Experience: • Somalogic • Pfizer • NIH Leadership: Bring Operational Experience to Business of Science David King, PhD SVP, Global R&D Experience: • IntegenX • Affymetrix • Guava Mona Abou-Sayed SVP, SBS Experience: • Mitel • Danaher • Tektronix Anders Davas SVP, Global Operations Experience: • Danaher • Mölnlycke • Telair 5

CONSUMABLES INSTRUMENTS SERVICES Tactics: Climb the Value PYRAMID, Expand the Customer PIE ACADEMIC $13B1 BIOPHARMA $27B1 CURRENT (Q3 YTD) PRODUCT MIX CONSUMABLES INSTRUMENTS SERVICES FUTURE PRODUCT MIX2 53%* Q3 YTD GROSS MARGINS 65% TARGET GROSS MARGINS CURRENT END MARKETS 1Management estimate 2Anticipated BIOPRODUCTION $22B1 APPLIED & INDUSTRIAL $10B1 PHARMA ACADEMIC & & BIOTECH GOVERNMENT $27B1 $13B1 FUTURE END MARKETS CLINICAL $40B1 35%* 16%* 49%*,** APPLIED & INDUSTRIAL $10B1 • APPLYING M&A to add products, customers, and end-markets • TARGETING consumables with higher margins at top of pyramid • FOCUSING on instruments with high pull through relative to ASP • EXPANDING service offerings to increase technology adoption CLIMB UP TOWARDS MARGIN EXPAND FOR TAM & GROWTH 6 *Non-GAAP gross margin excludes amortization of developing technology, non-cash stock-based compensation, and depreciation and amortization. Refer to Appendix for a reconciliation between GAAP and non-GAAP gross margin **Includes 2% of other revenue

Environment Needing a Partner Like Standard BioTools Emerging Life Science Tools & Biopharma Markets Difficulties Create Consolidation Opportunity $0 $10 $20 $30 $40 $50 $60 Jan '22 Jan '23 Jan '24 Jan '25 Avg. Share Price Valuation & Sales Decreases in LS Tools1 1Average share price of 13 emerging life sciences companies 7% revenue decrease in '23, and 9% decrease through Q3 '24 80% decrease in valuation Private Tools Financing Activity Down3 Public Tools Equity Financing Dried Up2 $0.0 $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 2021 2022 2023 2024 $- $5 $10 $15 0 10 20 30 40 50 2021 2022 2023 2024 # IPOs # FOs # RDs Total ($B) ‘24 equity issuance ($) down 93% compared to ‘21 $14B $1B $1B $1B Venture investment activity down 53% compared to ‘21 Standard BioTools has the platform to consolidate life science tools companies facing these challenges, under one channel, to create broader value to customers and return to shareholders. 2Cowen $ in billions 7 3HSBC

M&A Pipeline: Disciplined Criteria and Filling Funnel 8 Consumables Instrument Services DIVERSIFIES PRODUCT MIX & END MARKET • High margin recurring consumables • Diversified product mix • Growth in pharma and new end markets DE-RISKED TECHNOLOGY • Science fully understood • Deployable product PATH TO COMMERCIALIZATION • Clear unmet need & product market fit • Rigorously validated • Systematic VOC work SBS SYNERGIES • Accelerate Sales/Adoption • Leverage global scale • Ops and Manufacturing Academic Pharma Applied/Ag/Industrial PRIMARY END MARKET Bioprocessing Clinical M&A FOCUS & CRITERIA